Notably, objective response and PFS with HX008 combined with irinotecan was independent of tumor PD-L1 expression, whereas OS benefit tends to be more apparent in patients with PD-L1 positive tumors (CPS ≥1). The gene discussed is CD274; the disease is neoplasm.